U.S. Commercial Services Stock News

This article examines whether Zimmer Biomet Holdings, trading at around US$87.64, appears to be a bargain or a value trap by exploring what the current price may be implying about the stock. The share price has declined 1.6% over the past week, 11.9% over the past month, and 20.0% over the last year, which can influence how the market views both its risk and potential. Recent coverage has focused on how Zimmer Biomet fits within the broader medical equipment space and how investors are...

AES (NYSE:AES) has reached a new milestone in utility-scale solar construction at its Bellefield complex. The company has moved Maximo's AI-powered robotic solar installation system from pilot use to commercial production. This large-scale deployment focuses on faster, safer solar construction while addressing labor constraints. For investors tracking NYSE:AES, this development comes with the stock recently trading at $14.06 and a 1 year return of 19.0%, while longer term 3 year and 5 year...

A shareholder proposal giving investors the right to act by written consent has been submitted at BorgWarner ahead of the upcoming annual meeting. BorgWarner's board has recommended a vote against the proposal, creating a clear split between management and the proponent. The outcome could influence how NYSE:BWA shareholders exercise governance rights between annual meetings. BorgWarner, trading as NYSE:BWA, is entering the annual meeting with governance in focus and a share price of $56.12...

How Novo Nordisk’s recent performance sets up the current valuation debate Novo Nordisk (NYSE:NVO) has recently seen weak share price performance, with negative returns over the past month, past 3 months and year, putting fresh attention on how its current valuation lines up with fundamentals. See our latest analysis for Novo Nordisk. Recent trading has been weak, with a 30 day share price return of 8.33% and a year to date share price return of 30.65%. The 1 year total shareholder return of...

On March 19, 2026, Hub Group, Inc. received an expected Nasdaq deficiency notice after failing to file its 2025 Form 10-K on time, following the discovery of a US$77 million understatement of purchased transportation expenses, although its Class A common stock continues to trade on the Nasdaq Global Select Market. While the notice does not immediately affect trading, it intensifies scrutiny of Hub Group’s financial controls, governance, and ability to resolve reporting issues within Nasdaq’s...

AI powered autonomous agents such as Anthropic's Claude are emerging as cross platform tools that can handle complex workflows typically managed by enterprise software. Investors are starting to question how this could affect the role of traditional application layer providers, including Manhattan Associates (NasdaqGS:MANH), particularly around pricing power and profitability. This development has recently drawn more attention, yet it has not been a core focus of recent coverage that...

Q3 2026 Earnings Snapshot Cintas (CTAS) has just reported Q3 2026 results with quarterly revenue of about US$2.8b and basic EPS of US$1.23, giving investors a fresh read on how the business is tracking this year. Over recent quarters the company has seen revenue move from US$2.50b in Q1 2025 to US$2.80b in Q2 2026, while basic EPS has shifted from US$1.12 to US$1.23, with trailing twelve month net profit margins around 17.5% helping to frame the quality of those earnings. See our full...

In recent days, Broadcom and Carahsoft revealed they previously secured a five-year, US$970 million blanket purchase agreement with the Defense Information Systems Agency to streamline VMware Cloud Foundation–based private cloud and security software procurement across multiple U.S. defense agencies. Together with Broadcom’s new Symantec CBX security platform and advanced AI networking and optical launches, this federal contract highlights how the company is tying government, cybersecurity,...

Daktronics (DAKT) is back in the spotlight after announcing three fresh major league baseball projects, including a new Mariners Fire TV outfield board in Seattle and large center field displays in Phoenix and Chicago. See our latest analysis for Daktronics. The recent major league baseball wins sit against a mixed share price backdrop, with a 7 day share price return of 5.88%, a 30 day share price return of 22.11% and a 1 year total shareholder return of 69.73%. This indicates that longer...

Wondering if Alkermes at around US$29.37 is a bargain or already pricing in its prospects? This article walks through how the numbers stack up so you can judge the value for yourself. The stock has returned 8.0% over the last 7 days, while the 30 day return is an 8.8% decline, with year to date performance at 3.9% and a 12.8% decline over the past year. Recent coverage has focused on Alkermes as a listed US pharmaceuticals and biotech name, putting attention on how investors are weighing its...

Green Brick Partners (GRBK) has drawn fresh attention after highlighting Rainwater Crossing, a new master-planned community in Celina, Texas, developed with HFI Capital Management and anchored by multiple builders and amenity rich public spaces. See our latest analysis for Green Brick Partners. The Rainwater Crossing update comes as Green Brick Partners trades at US$64.01, with a 1-day share price return of 1.23%, a recent 30-day share price decline of 17.79%, and a 5-year total shareholder...

Epsilon Energy (EPSN) has just posted its FY 2025 numbers with third quarter revenue of about US$9.0 million and basic EPS of US$0.05, set against trailing twelve month revenue of US$45.7 million and EPS of US$0.27 that came alongside 11.2% earnings growth and a trailing net margin of 12.9% compared with 17% a year earlier. Over recent quarters the company has seen revenue move from US$7.3 million in Q2 2024 to US$16.2 million in Q1 2025, then to US$9.0 million in Q3 2025. Quarterly EPS has...

In March 2026, MINISO Group Holding Limited issued earnings guidance for fiscal 2025, projecting revenue of about RMB 21.44 billion–RMB 21.45 billion, operating profit of roughly RMB 3.30 billion, adjusted operating profit of about RMB 3.67 billion, and profit of around RMB 1.32 billion–RMB 1.33 billion, driven by a richer product portfolio, stronger brand recognition, and broader, more efficient sales channels. An interesting twist is that, despite the projected revenue growth and higher...

BioStem Technologies (OTCPK:BSEM) appointed Jodi Ungrodt as a new member of its Board of Directors and Chair of the Audit Committee. The company completed the acquisition of BioTissue Holdings Inc.'s surgical and wound assets, including a national sales force. The transaction expands BioStem's commercial reach into hospital settings and broadens its product portfolio. BioStem Technologies, trading at $4.92, sits at an interesting point in its share price history, with a 25.9% return year to...

Biohaven announced it has completed enrollment in a Phase 2 proof-of-concept trial of taldefgrobep alfa, a myostatin-activin pathway inhibitor being tested as a self-administered, dose-ranging monotherapy for overweight and obesity across 20 U.S. sites, with topline data expected in the second half of 2026. The program is drawing attention because taldefgrobep alfa aims to deliver high-quality weight loss by reducing fat mass while preserving or increasing lean muscle, a profile that differs...

If you are wondering whether AMETEK at around US$215 per share looks expensive or offers value, it is helpful to separate price action from underlying worth. The stock has seen mixed moves recently, with a 1.2% gain over the last 7 days, a 7.0% decline over 30 days, and returns of 3.0% year to date, 22.5% over the past year, 54.4% over 3 years, and 74.2% over 5 years. These moves come alongside a steady stream of company updates and industry commentary that keep AMETEK on many investors'...

Relief rally puts Norwegian Cruise Line Holdings (NCLH) back in focus A broad relief rally in travel stocks, sparked by a delayed military strike in Iran and renewed diplomatic talks in the Middle East, pushed Norwegian Cruise Line Holdings (NCLH) sharply higher on Monday. With geopolitical risk briefly easing and cruise peers also gaining, investors are reassessing how headline driven moves might affect NCLH’s risk profile, recent returns and valuation against other consumer cyclical...

In recent days, Wells Fargo and Jefferies upgraded ONEOK, citing how geopolitical tensions and shifting global energy flows could benefit its U.S. midstream network, including assets such as the Eiger Express Pipeline expansion and the Bighorn processing plant. The upgrades highlight how ONEOK’s existing pipeline and processing footprint may gain importance as buyers seek more reliable natural gas and NGL supply routes amid global disruptions. Next, we’ll explore how this geopolitical-driven...

Zhihu (NYSE:ZH) has posted a mixed FY 2025 update, with Q3 revenue at C¥658.9 million and basic EPS of C¥0.58 loss per share, while trailing 12 month figures show revenue of C¥2.97 billion and basic EPS of C¥1.25. Over recent quarters, revenue has shifted from C¥933.8 million in Q2 2024 to C¥859.2 million in Q4 2024, then to C¥716.9 million in Q2 2025 and C¥658.9 million in Q3 2025. Net income moved from a C¥82.7 million loss in Q2 2024 to a C¥72.5 million profit in Q2 2025, before a C¥46.7...

Why Flywire is On Investors’ Radar Today Flywire (FLYW) has been drawing attention after a stretch where its share price showed a mix of gains over the past month and declines across the past 3 months and year to date. Investors are weighing how this recent trading pattern lines up with the company’s fundamentals and global payments footprint. See our latest analysis for Flywire. With the share price at $12.40, Flywire’s recent 16.5% 1 month share price return contrasts with its 14.3% 3 month...

Recent share performance and business snapshot W. R. Berkley (WRB) has seen recent share pressure, with the stock showing negative returns over the past week, month, and past 3 months. Its 1 year and multi year total returns remain positive. The commercial insurer reports revenue of US$14,707.856m and net income of US$1,779.403m. Annual revenue growth is 0.40% and net income growth is 2.62%, supported by operations across Insurance and Reinsurance & Monoline Excess segments. See our latest...

Glass House Brands (OTCPK:GLAS.F) has just posted a mixed FY 2025 picture, with Q3 revenue of US$38.4 million and a basic EPS loss of US$0.19, set against trailing 12 month revenue of US$196.2 million and a basic EPS loss of US$0.23. Over recent quarters, the company has seen revenue range from US$53.0 million in Q4 2024 to US$59.9 million in Q2 2025, while basic EPS has swung between a profit of US$0.10 in Q4 2024 and a loss of US$0.19 in Q3 2025. This keeps the focus firmly on how...

Oklo Inc. reported a full-year 2025 net loss of US$105.66 million, compared with US$73.62 million a year earlier, while basic loss per share from continuing operations narrowed slightly to US$0.72 from US$0.74. At the same time, Oklo secured a U.S. Department of Energy Other Transaction Agreement and key Nuclear Safety Design Agreement approvals that advance its first Aurora reactor and fuel fabrication facility at Idaho National Laboratory under the DOE’s Reactor and Fuel Line Pilot...

Vera Therapeutics (VERA) has been drawing attention after a long run of clinical development work in immunological kidney and viral diseases, prompting investors to reassess the stock’s recent performance and risk profile. See our latest analysis for Vera Therapeutics. Vera Therapeutics’ share price has cooled recently, with a 30 day share price return showing a decline of 4.52% and a 90 day share price return showing a decline of 27.86%, even though the 1 year total shareholder return is 55%...